Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Abilify Maintena

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT03376763Phase 4Completed

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

Showing all 1 trials

Research Network

Common Treatments

  • Abilify Maintena1

Active Sponsors

  • Korea Otsuka Pharmaceutical Co., Ltd.1

Top Investigators

Related Conditions

  • Longacting Injection1
  • Antipsychotics1
  • Schizophrenia1
  • Lai1

Activity Timeline